Want to see JP:4569 full AI Analyst Report?
Top Page
KYORIN Pharmaceutical Co.,Ltd.
(4569)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥1,129.00
▼(-6.77% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weakened FY2026 profitability and an inconsistent multi-year free-cash-flow profile, despite a conservatively financed balance sheet. Technicals add further pressure as the stock trades below key moving averages with negative MACD. Valuation is mixed: a strong dividend yield helps, but a high P/E limits upside support.
Positive Factors
Conservative Balance Sheet
Low leverage and continued equity growth provide financial flexibility to absorb earnings volatility, fund pharmaceutical development, and maintain operations without excessive dependence on external borrowing.
Negative Factors
FY2026 Revenue Decline
The latest revenue contraction interrupts the prior multi-year upward trend and may indicate weaker prescription demand, product mix pressure, competition, or reimbursement effects. Sustained declines would reduce operating leverage and constrain investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and continued equity growth provide financial flexibility to absorb earnings volatility, fund pharmaceutical development, and maintain operations without excessive dependence on external borrowing.
Read all positive factors
KYORIN Pharmaceutical Co.,Ltd. (4569) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥62.06B
Dividend Yield4.87%
Average Volume (3M)127.03K
Price to Earnings (P/E)31.0
Beta (1Y)0.47
Revenue Growth-4.71%
EPS Growth-78.91%
CountryJP
Employees1,982
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)37.80
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.85
Revenue Forecast (FY)¥123.03B
KYORIN Pharmaceutical Co.,Ltd. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diver...
How the Company Makes Money
KYORIN Pharmaceutical primarily makes money from (1) sales of prescription pharmaceuticals and (2) income tied to out-licensing/commercialization arrangements for certain products.
1) Prescription drug sales (core revenue stream)
- Product revenu...
KYORIN Pharmaceutical Co.,Ltd. Financial Statement Overview
Summary
Income Statement
54
Neutral
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 125.68B | 126.26B | 130.09B | 119.53B | 113.27B | 105.53B |
| Gross Profit | 50.53B | 51.61B | 59.51B | 51.62B | 50.16B | 49.44B |
| EBITDA | 6.82B | 8.22B | 17.15B | 10.52B | 8.96B | 8.72B |
| Net Income | 2.17B | 3.45B | 9.09B | 5.47B | 4.72B | 3.93B |
Balance Sheet | ||||||
| Total Assets | 188.61B | 195.46B | 193.62B | 177.63B | 176.04B | 171.92B |
| Cash, Cash Equivalents and Short-Term Investments | 16.95B | 15.08B | 16.51B | 13.98B | 19.39B | 27.49B |
| Total Debt | 23.24B | 23.79B | 28.44B | 20.95B | 21.28B | 21.62B |
| Total Liabilities | 48.30B | 53.02B | 57.33B | 46.89B | 50.58B | 47.41B |
| Stockholders Equity | 140.30B | 142.43B | 136.28B | 130.74B | 125.46B | 124.51B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.52B | -2.19B | -4.23B | -4.32B | 3.90B |
| Operating Cash Flow | 0.00 | 6.38B | 3.51B | 1.55B | 2.01B | 6.35B |
| Investing Cash Flow | 0.00 | -1.64B | -6.32B | -3.19B | -6.28B | -2.56B |
| Financing Cash Flow | 0.00 | -7.96B | 3.95B | -3.35B | -3.36B | -4.11B |
KYORIN Pharmaceutical Co.,Ltd. Technical Analysis
Neutral
1211.00
Price Trends
1149.30
Positive
1293.73
Negative
1417.00
Negative
Market Momentum
2.75
Negative
56.02
Neutral
86.71
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4569, the sentiment is Neutral. The current price of 1211 is above the 20-day moving average (MA) of 1131.85, above the 50-day MA of 1149.30, and below the 200-day MA of 1417.00, indicating a neutral trend. The MACD of 2.75 indicates Negative momentum. The RSI at 56.02 is Neutral, neither overbought nor oversold. The STOCH value of 86.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4569.
KYORIN Pharmaceutical Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥242.94B | 7.68 | ― | 2.12% | 12.23% | 3.35% | |
68 Neutral | ¥113.49B | 12.69 | 5.81% | 2.34% | 14.72% | 52.55% | |
64 Neutral | ¥167.88B | 12.17 | 6.37% | 2.60% | 10.35% | 16.60% | |
63 Neutral | ¥144.62B | 14.65 | 1.46% | 4.85% | -6.86% | -17.71% | |
52 Neutral | ¥62.06B | 30.95 | ― | 4.71% | -4.71% | -78.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥194.89B | 23.40 | 2.92% | 2.14% | 6.78% | -48.34% |
* Healthcare Sector Average
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,170.00
-291.28
-19.93%
JP:4521
Kaken Pharmaceutical Co
3,990.00
360.55
9.93%
JP:4547
Kissei Pharmaceutical Co
4,105.00
-43.10
-1.04%
JP:4553
Towa Pharmaceutical Co
3,930.00
1,022.56
35.17%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,290.00
236.34
7.74%
JP:4516
Nippon Shinyaku Co., Ltd.
3,598.00
595.09
19.82%
KYORIN Pharmaceutical Co.,Ltd. Corporate Events
KYORIN to Promote World’s First Cream Treatment for Allergic Conjunctivitis in Partnership with Santen
Aug 3, 2026
KYORIN Pharmaceutical will begin promotion of Alesion eyelid cream 0.5%, a once-daily, long-acting treatment for allergic conjunctivitis, from August 17, 2026 under a joint marketing deal with Santen Pharmaceutical. Santen will handle manufacturin...
KYORIN Pharmaceutical Details Q1 Results and Pipeline Outlook for FY2027
Jul 30, 2026
KYORIN Pharmaceutical Co., Ltd., a Japan-based drug manufacturer, specializes in developing and selling prescription pharmaceuticals while maintaining an active pipeline of medicines under development. The company’s operations encompass cons...
KYORIN Pharmaceutical Warns of Profit Slump and Dividend Cut Despite Strong Balance Sheet
Jul 30, 2026
KYORIN Pharmaceutical reported consolidated net sales of ¥29.65 billion for the three months ended June 30, 2026, down 1.9% year on year, while operating profit plunged 59.3% to ¥964 million and profit attributable to owners of parent fe...
KYORIN, Santen Team Up to Expand Marketing of Novel Allergic Conjunctivitis Cream in Japan
Jul 13, 2026
KYORIN Pharmaceutical has entered a joint marketing agreement in Japan with ophthalmology specialist Santen Pharmaceutical for Alesion eyelid cream 0.5%, a long-acting treatment for allergic conjunctivitis. Under the deal, Santen will continue man...
KYORIN Pharmaceutical Keeps Annual Dividend Steady at ¥57 Per Share
May 20, 2026
KYORIN Pharmaceutical’s board has approved a year-end dividend of ¥37 per share for shareholders of record as of March 31, 2026, funded from retained earnings. Combined with an interim dividend of ¥20, this brings the total annual ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.